We are live on
!
Find out more
PCM
Puissance Capital Management Portfolio holdings
AUM
$17.3M
1-Year Est. Return
149.36%
This Fund
S&P 500
This Quarter
Est. Return
+25.58%
1 Year Est. Return
+149.36%
3 Year Est. Return
+115.5%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$40.3M
AUM Growth
-$4.52M
(-10%)
Cap. Flow
-$9.05M
Cap. Flow
% of AUM
-22.45%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
2
Closed
1
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
+$7.53M |
| 2 |
TCON
TRACON Pharmaceuticals, Inc. Common Stock
TCON
|
+$1.26M |
| 3 |
SCYNEXIS
SCYX
|
+$260K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.92% |
| 2 | Healthcare | 1.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VRAY
1
DELISTED
ViewRay, Inc.
VRAY
| $28.9M | 71.64% |
6,842,975
| – | – |
|
|
CHRN
2
ChronoScale Holdings
CHRN
$2.69B
| $8.03M | 19.92% |
91,266
| – | – |
|
|
BLPH
3
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
| $2.9M | 7.2% |
553,250
| – | – |
|
4
Corvus Pharmaceuticals
CRVS
$1.1B
| $207K | 0.51% |
38,010
| – | – |
|
|
TCON
5
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $178K | 0.44% |
3,802
-19,207
| -83% | -$1.26M |
|
|
6
SCYNEXIS
SCYX
$37.4M
| $115K | 0.29% |
1,586
-3,149
| -67% | -$260K |
|
|
KDMN
7
DELISTED
Kadmon Holdings, Inc.
KDMN
| – | – |
-3,020,596
| Closed | -$7.53M |
|
Similar funds
FM
IAM
FP
AF
TCS
JJ
PCM
NC
Puissance Capital Management's Q4 2019 Portfolio in Review
As of Q4 2019, Puissance Capital Management held 7 positions worth $40.3M, down 10% from $44.8M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Puissance Capital Management withdrew a net $9.05M in Q4 2019, closing 1 position and reducing 2 holdings. Its most notable exit was Kadmon Holdings, Inc., an estimated $7.53M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 24% a quarter earlier, followed by Healthcare.
- Puissance Capital Management's biggest Q4 2019 reduction was TRACON Pharmaceuticals, Inc. Common Stock, cutting an estimated $1.26M.
- Puissance Capital Management fully exited Kadmon Holdings, Inc. in Q4 2019, selling an estimated $7.53M.
- Puissance Capital Management's ten largest holdings make up 100% of its $40.3M portfolio in Q4 2019.
- Puissance Capital Management opened 0 new positions and closed 1 in Q4 2019.
- Puissance Capital Management's portfolio value fell 10% quarter-over-quarter to $40.3M.
Based on Puissance Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.